KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML/RARα.

Xinrui WangHuiyong FanCongling XuGuojuan JiangHaiwei WangXinrui Wang

Published in: Cancer cell international (2019)

Our study suggested that KDM3B was able to inhibit APL progression by maintaining chromatin in a compact state and facilitating the ATRA-mediated degradation of PML/RARα. Taken together, the results show that KDM3B may be an alternative target for the treatment regimens and the targeted therapy for APL by sustaining the function of PML/RARα fusion protein.

Keyphrases

gene expression
dna damage
transcription factor
genome wide
signaling pathway
oxidative stress
replacement therapy
low cost